Loading…
Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis
Elevated levels of fibroblast growth factor 23 (FGF23) and phosphorus (P) have been linked to greater risks of left ventricular hypertrophy (LVH) in patients with end stage renal disease (ESRD). The aim of this study was to test if differences exist in a long nocturnal HD group in comparison with a...
Saved in:
Published in: | Therapeutic apheresis and dialysis 2013-08, Vol.17 (4), p.407-411 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83 |
---|---|
cites | cdi_FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83 |
container_end_page | 411 |
container_issue | 4 |
container_start_page | 407 |
container_title | Therapeutic apheresis and dialysis |
container_volume | 17 |
creator | Knap, Bojan Večerić-Haler, Željka Benedik, Miha Buturović-Ponikvar, Jadranka Ponikvar, Rafael Bren, Andrej F |
description | Elevated levels of fibroblast growth factor 23 (FGF23) and phosphorus (P) have been linked to greater risks of left ventricular hypertrophy (LVH) in patients with end stage renal disease (ESRD). The aim of this study was to test if differences exist in a long nocturnal HD group in comparison with a group treated with standard daily thrice weekly dialysis. The attempt was to evaluate if elevated FGF‐23 levels, intact parathyroid hormone and P might be associated with left ventricular mass index (LVMI). Quantitative echocardiographic analyses were performed at baseline in 50 maintenance HD patients (17 women and 33 men, mean age: 56.4 ± 15.35 years, mean HD vintage: 9.06 ± 8.86 years, all patients are on HD thrice a week‐median duration 15 h/week, 10 of them on long nocturnal HD, median duration 24 h/week). LVMIs were calculated. FGF23 was measured in duplicate using a second generation C‐terminal enzyme‐linked immunosorbent assay and log of FGF‐23 values were computed. Mean LVMI was 136.44 ± 44.44 g/m2. Serum FGF‐23 levels were elevated when compared to population data with preserved kidney function (median 1388.5 RU/mL, range 252 to 24 336 RU/mL). There were no correlations recorded between log FGF‐23 levels and LVMI (r = 0.2, P = 0.66). LVMI was significantly lower in HD patients on long nocturnal dialysis procedure (r = −0.31, P = 0.05). Patients treated with long nocturnal HD showed lower LV mass, lower P‐values and higher 25‐OH‐D3 supply. Plasma FGF‐23 concentration was comparable between the groups and was not associated with LVMI in our maintenance HD patients. |
doi_str_mv | 10.1111/1744-9987.12087 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1420169411</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1420169411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83</originalsourceid><addsrcrecordid>eNqFkc1uEzEURi0EoqWwZoe8ZDOtfya2h10VkbRVKJEIAbGxPJ47YJjYxfaozUPwznVIG4kV3tjXOt9ZfBeh15Sc0nLOqKzrqmmUPKWMKPkEHR9-nh7esjlCL1L6SQhjNefP0RHjDadKkWP0Z-baGNrBpIznMdzmH3hmbA4RM46N7_AC-ozX4HN0dhxMxB9MSvjSd3CHnS-T8xm88RbwBWxC58ywTS7hpcmupNI7_CkXj4ldscQ0JrwI_ju-DjaP0Zvhn9RL9Kw3Q4JXD_cJ-jx7v5peVIuP88vp-aKytaSyalWvpCBCqZ40Xc2oILWQnRSCW2Z7YoUF09RUsJZOgDKrCAfTGwUT2ppO8RP0du-9ieH3CCnrjUsWhsF4CGPStGaEimKgBT3bozaGlCL0-ia6jYlbTYne7UDvWta7xvXfHZTEmwf52G6gO_CPpRdgsgdu3QDb__n06nz5KK72OZcy3B1yJv7SQnI50V-u5_rq63K6_rZq9JrfAw1FoZs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1420169411</pqid></control><display><type>article</type><title>Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis</title><source>Wiley</source><creator>Knap, Bojan ; Večerić-Haler, Željka ; Benedik, Miha ; Buturović-Ponikvar, Jadranka ; Ponikvar, Rafael ; Bren, Andrej F</creator><creatorcontrib>Knap, Bojan ; Večerić-Haler, Željka ; Benedik, Miha ; Buturović-Ponikvar, Jadranka ; Ponikvar, Rafael ; Bren, Andrej F</creatorcontrib><description>Elevated levels of fibroblast growth factor 23 (FGF23) and phosphorus (P) have been linked to greater risks of left ventricular hypertrophy (LVH) in patients with end stage renal disease (ESRD). The aim of this study was to test if differences exist in a long nocturnal HD group in comparison with a group treated with standard daily thrice weekly dialysis. The attempt was to evaluate if elevated FGF‐23 levels, intact parathyroid hormone and P might be associated with left ventricular mass index (LVMI). Quantitative echocardiographic analyses were performed at baseline in 50 maintenance HD patients (17 women and 33 men, mean age: 56.4 ± 15.35 years, mean HD vintage: 9.06 ± 8.86 years, all patients are on HD thrice a week‐median duration 15 h/week, 10 of them on long nocturnal HD, median duration 24 h/week). LVMIs were calculated. FGF23 was measured in duplicate using a second generation C‐terminal enzyme‐linked immunosorbent assay and log of FGF‐23 values were computed. Mean LVMI was 136.44 ± 44.44 g/m2. Serum FGF‐23 levels were elevated when compared to population data with preserved kidney function (median 1388.5 RU/mL, range 252 to 24 336 RU/mL). There were no correlations recorded between log FGF‐23 levels and LVMI (r = 0.2, P = 0.66). LVMI was significantly lower in HD patients on long nocturnal dialysis procedure (r = −0.31, P = 0.05). Patients treated with long nocturnal HD showed lower LV mass, lower P‐values and higher 25‐OH‐D3 supply. Plasma FGF‐23 concentration was comparable between the groups and was not associated with LVMI in our maintenance HD patients.</description><identifier>ISSN: 1744-9979</identifier><identifier>EISSN: 1744-9987</identifier><identifier>DOI: 10.1111/1744-9987.12087</identifier><identifier>PMID: 23931880</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Echocardiography ; Enzyme-Linked Immunosorbent Assay ; Female ; Fibroblast growth factor-23 ; Fibroblast Growth Factors - blood ; Heart Ventricles - pathology ; Hemodialysis ; Humans ; Hypertrophy, Left Ventricular - etiology ; Intact parathyroid hormone ; Kidney Failure, Chronic - therapy ; Left ventricular hypertrophy ; Male ; Middle Aged ; Nocturnal hemodialysis ; Parathyroid Hormone - blood ; Phosphorus - blood ; Prospective Studies ; Renal Dialysis - methods ; Time Factors</subject><ispartof>Therapeutic apheresis and dialysis, 2013-08, Vol.17 (4), p.407-411</ispartof><rights>2013 The Authors. Therapeutic Apheresis and Dialysis © 2013 International Society for Apheresis</rights><rights>2013 The Authors. Therapeutic Apheresis and Dialysis © 2013 International Society for Apheresis.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83</citedby><cites>FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23931880$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Knap, Bojan</creatorcontrib><creatorcontrib>Večerić-Haler, Željka</creatorcontrib><creatorcontrib>Benedik, Miha</creatorcontrib><creatorcontrib>Buturović-Ponikvar, Jadranka</creatorcontrib><creatorcontrib>Ponikvar, Rafael</creatorcontrib><creatorcontrib>Bren, Andrej F</creatorcontrib><title>Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis</title><title>Therapeutic apheresis and dialysis</title><addtitle>Ther Apher Dial</addtitle><description>Elevated levels of fibroblast growth factor 23 (FGF23) and phosphorus (P) have been linked to greater risks of left ventricular hypertrophy (LVH) in patients with end stage renal disease (ESRD). The aim of this study was to test if differences exist in a long nocturnal HD group in comparison with a group treated with standard daily thrice weekly dialysis. The attempt was to evaluate if elevated FGF‐23 levels, intact parathyroid hormone and P might be associated with left ventricular mass index (LVMI). Quantitative echocardiographic analyses were performed at baseline in 50 maintenance HD patients (17 women and 33 men, mean age: 56.4 ± 15.35 years, mean HD vintage: 9.06 ± 8.86 years, all patients are on HD thrice a week‐median duration 15 h/week, 10 of them on long nocturnal HD, median duration 24 h/week). LVMIs were calculated. FGF23 was measured in duplicate using a second generation C‐terminal enzyme‐linked immunosorbent assay and log of FGF‐23 values were computed. Mean LVMI was 136.44 ± 44.44 g/m2. Serum FGF‐23 levels were elevated when compared to population data with preserved kidney function (median 1388.5 RU/mL, range 252 to 24 336 RU/mL). There were no correlations recorded between log FGF‐23 levels and LVMI (r = 0.2, P = 0.66). LVMI was significantly lower in HD patients on long nocturnal dialysis procedure (r = −0.31, P = 0.05). Patients treated with long nocturnal HD showed lower LV mass, lower P‐values and higher 25‐OH‐D3 supply. Plasma FGF‐23 concentration was comparable between the groups and was not associated with LVMI in our maintenance HD patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Echocardiography</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Fibroblast growth factor-23</subject><subject>Fibroblast Growth Factors - blood</subject><subject>Heart Ventricles - pathology</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Hypertrophy, Left Ventricular - etiology</subject><subject>Intact parathyroid hormone</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Left ventricular hypertrophy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nocturnal hemodialysis</subject><subject>Parathyroid Hormone - blood</subject><subject>Phosphorus - blood</subject><subject>Prospective Studies</subject><subject>Renal Dialysis - methods</subject><subject>Time Factors</subject><issn>1744-9979</issn><issn>1744-9987</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkc1uEzEURi0EoqWwZoe8ZDOtfya2h10VkbRVKJEIAbGxPJ47YJjYxfaozUPwznVIG4kV3tjXOt9ZfBeh15Sc0nLOqKzrqmmUPKWMKPkEHR9-nh7esjlCL1L6SQhjNefP0RHjDadKkWP0Z-baGNrBpIznMdzmH3hmbA4RM46N7_AC-ozX4HN0dhxMxB9MSvjSd3CHnS-T8xm88RbwBWxC58ywTS7hpcmupNI7_CkXj4ldscQ0JrwI_ju-DjaP0Zvhn9RL9Kw3Q4JXD_cJ-jx7v5peVIuP88vp-aKytaSyalWvpCBCqZ40Xc2oILWQnRSCW2Z7YoUF09RUsJZOgDKrCAfTGwUT2ppO8RP0du-9ieH3CCnrjUsWhsF4CGPStGaEimKgBT3bozaGlCL0-ia6jYlbTYne7UDvWta7xvXfHZTEmwf52G6gO_CPpRdgsgdu3QDb__n06nz5KK72OZcy3B1yJv7SQnI50V-u5_rq63K6_rZq9JrfAw1FoZs</recordid><startdate>201308</startdate><enddate>201308</enddate><creator>Knap, Bojan</creator><creator>Večerić-Haler, Željka</creator><creator>Benedik, Miha</creator><creator>Buturović-Ponikvar, Jadranka</creator><creator>Ponikvar, Rafael</creator><creator>Bren, Andrej F</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201308</creationdate><title>Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis</title><author>Knap, Bojan ; Večerić-Haler, Željka ; Benedik, Miha ; Buturović-Ponikvar, Jadranka ; Ponikvar, Rafael ; Bren, Andrej F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Echocardiography</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Fibroblast growth factor-23</topic><topic>Fibroblast Growth Factors - blood</topic><topic>Heart Ventricles - pathology</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Hypertrophy, Left Ventricular - etiology</topic><topic>Intact parathyroid hormone</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Left ventricular hypertrophy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nocturnal hemodialysis</topic><topic>Parathyroid Hormone - blood</topic><topic>Phosphorus - blood</topic><topic>Prospective Studies</topic><topic>Renal Dialysis - methods</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Knap, Bojan</creatorcontrib><creatorcontrib>Večerić-Haler, Željka</creatorcontrib><creatorcontrib>Benedik, Miha</creatorcontrib><creatorcontrib>Buturović-Ponikvar, Jadranka</creatorcontrib><creatorcontrib>Ponikvar, Rafael</creatorcontrib><creatorcontrib>Bren, Andrej F</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Therapeutic apheresis and dialysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knap, Bojan</au><au>Večerić-Haler, Željka</au><au>Benedik, Miha</au><au>Buturović-Ponikvar, Jadranka</au><au>Ponikvar, Rafael</au><au>Bren, Andrej F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis</atitle><jtitle>Therapeutic apheresis and dialysis</jtitle><addtitle>Ther Apher Dial</addtitle><date>2013-08</date><risdate>2013</risdate><volume>17</volume><issue>4</issue><spage>407</spage><epage>411</epage><pages>407-411</pages><issn>1744-9979</issn><eissn>1744-9987</eissn><abstract>Elevated levels of fibroblast growth factor 23 (FGF23) and phosphorus (P) have been linked to greater risks of left ventricular hypertrophy (LVH) in patients with end stage renal disease (ESRD). The aim of this study was to test if differences exist in a long nocturnal HD group in comparison with a group treated with standard daily thrice weekly dialysis. The attempt was to evaluate if elevated FGF‐23 levels, intact parathyroid hormone and P might be associated with left ventricular mass index (LVMI). Quantitative echocardiographic analyses were performed at baseline in 50 maintenance HD patients (17 women and 33 men, mean age: 56.4 ± 15.35 years, mean HD vintage: 9.06 ± 8.86 years, all patients are on HD thrice a week‐median duration 15 h/week, 10 of them on long nocturnal HD, median duration 24 h/week). LVMIs were calculated. FGF23 was measured in duplicate using a second generation C‐terminal enzyme‐linked immunosorbent assay and log of FGF‐23 values were computed. Mean LVMI was 136.44 ± 44.44 g/m2. Serum FGF‐23 levels were elevated when compared to population data with preserved kidney function (median 1388.5 RU/mL, range 252 to 24 336 RU/mL). There were no correlations recorded between log FGF‐23 levels and LVMI (r = 0.2, P = 0.66). LVMI was significantly lower in HD patients on long nocturnal dialysis procedure (r = −0.31, P = 0.05). Patients treated with long nocturnal HD showed lower LV mass, lower P‐values and higher 25‐OH‐D3 supply. Plasma FGF‐23 concentration was comparable between the groups and was not associated with LVMI in our maintenance HD patients.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>23931880</pmid><doi>10.1111/1744-9987.12087</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1744-9979 |
ispartof | Therapeutic apheresis and dialysis, 2013-08, Vol.17 (4), p.407-411 |
issn | 1744-9979 1744-9987 |
language | eng |
recordid | cdi_proquest_miscellaneous_1420169411 |
source | Wiley |
subjects | Adult Aged Echocardiography Enzyme-Linked Immunosorbent Assay Female Fibroblast growth factor-23 Fibroblast Growth Factors - blood Heart Ventricles - pathology Hemodialysis Humans Hypertrophy, Left Ventricular - etiology Intact parathyroid hormone Kidney Failure, Chronic - therapy Left ventricular hypertrophy Male Middle Aged Nocturnal hemodialysis Parathyroid Hormone - blood Phosphorus - blood Prospective Studies Renal Dialysis - methods Time Factors |
title | Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T04%3A34%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fibroblast%20Growth%20Factor%2023%20and%20Left%20Ventricular%20Mass%20Index%20in%20Maintenance%20Hemodialysis%20Patients:%20Standard%20Versus%20Long%20Nocturnal%20Hemodialysis&rft.jtitle=Therapeutic%20apheresis%20and%20dialysis&rft.au=Knap,%20Bojan&rft.date=2013-08&rft.volume=17&rft.issue=4&rft.spage=407&rft.epage=411&rft.pages=407-411&rft.issn=1744-9979&rft.eissn=1744-9987&rft_id=info:doi/10.1111/1744-9987.12087&rft_dat=%3Cproquest_cross%3E1420169411%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1420169411&rft_id=info:pmid/23931880&rfr_iscdi=true |